Published Online
on May 22, 2006

A more recent version of this article appeared on May 30, 2006

This Article Full Text (PDF) Data Supplement All Versions of this Article: 113/21/2509    most recent CIRCULATIONAHA.105.601930v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Elliott, C. G. Articles by Ward, K. Search for Related Content PubMed PubMed Citation Articles by Elliott, C. G. Articles by Ward, K. Related Collections Pulmonary biology and circulation Genetics of cardiovascular disease

Submitted on November 17, 2005
Revised on February 6, 2006
Accepted on March 24, 2006

Relationship of BMPR2 Mutations to Vasoreactivity in Pulmonary Arterial Hypertension

C. Gregory Elliott MD^*, Eric W. Glissmeyer BS, Gregory T. Havlena BS, John Carlquist PhD, Jason T. McKinney MS, Stuart Rich MD, Michael D. McGoon MD, Mary Beth Scholand MD, Miryoung Kim BS, Robert L. Jensen PhD, Jon W. Schmidt , and Kenneth Ward MD

From the LDS Hospital and the University of Utah School of Medicine (C.G.E., E.W.G., G.T.H., J.C., M.B.S., M.K., R.L.J., J.W.S.), Salt Lake City, Utah; Johns Hopkins University School of Medicine (G.T.H.), Baltimore, Md; the University of Hawaii (K.W.), Honolulu; the Mayo Clinic College of Medicine (M.D.M.), Rochester, Minn; the University of Chicago (S.R.), Chicago, Ill; and Idaho Technology, Inc (J.T.M.), Salt Lake City, Utah.

^* To whom correspondence should be addressed. E-mail: ldgellio{at}ihc.com.

Background--Vasoreactivity tests are fundamental in evaluating pulmonary arterial hypertension (PAH). Mutations of the transforming growth factor- type II receptor gene, BMPR2, predispose to the development of pulmonary hypertension and may alter the response to vasodilators. Previous investigations have not examined the relationship of BMPR2 mutations to vasoreactivity.

Methods and Results--We identified 133 consecutive unrelated patients with either idiopathic or familial PAH. Sixty-six patients were excluded because we lacked either DNA samples (n=18) or complete data from a vasoreactivity test (n=48). The remaining 67 patients were screened for BMPR2 DNA sequence variations, and specific variations were confirmed by gene sequencing. The vasoreactivity of patients with nonsynonymous BMPR2 variations was compared with that of patients without nonsynonymous BMPR2 variations. We found nonsynonymous BMPR2 variations in 27 of 67 patients with idiopathic (n=16 of 52) or familial (n=11 of 15) PAH. Vasoreactivity was identified in 3.7% of 27 patients with nonsynonymous BMPR2 variations and in 35% of 40 patients without nonsynonymous BMPR2 variations (P=0.003). Five of the 27 nonsynonymous variations occur commonly in healthy individuals. None of the remaining 22 patients with BMPR2 variations demonstrated vasoreactivity, and the analysis remained unchanged when we assumed that nonsynonymous BMPR2 variations were present in all 15 patients with familial PAH.

Conclusions--Patients with familial or idiopathic PAH and nonsynonymous BMPR2 variations are unlikely to demonstrate vasoreactivity. Further trials are required to determine whether long-term therapy can be directed by tests for BMPR2 variations.

Key words: genetics • molecular biology • pulmonary arterial hypertension • vasoconstriction • vasodilation

This article has been cited by other articles:

				L. Dewachter, S. Adnot, C. Guignabert, L. Tu, E. Marcos, E. Fadel, M. Humbert, P. Dartevelle, G. Simonneau, R. Naeije, et al. Bone morphogenetic protein signalling in heritable versus idiopathic pulmonary hypertension Eur. Respir. J., November 1, 2009; 34(5): 1100 - 1110. [Abstract] [Full Text] [PDF]

				L B Smoot, D Obler, D B McElhinney, K Boardman, B-L Wu, V Lip, and M P Mullen Clinical features of pulmonary arterial hypertension in young people with an ALK1 mutation and hereditary haemorrhagic telangiectasia Arch. Dis. Child., July 1, 2009; 94(7): 506 - 511. [Abstract] [Full Text] [PDF]

				R. D. Machado, O. Eickelberg, C. G. Elliott, M. W. Geraci, M. Hanaoka, J. E. Loyd, J. H. Newman, J. A. Phillips III, F. Soubrier, R. C. Trembath, et al. Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S32 - S42. [Abstract] [Full Text] [PDF]

				G. Simonneau, I. M. Robbins, M. Beghetti, R. N. Channick, M. Delcroix, C. P. Denton, C. G. Elliott, S. P. Gaine, M. T. Gladwin, Z.-C. Jing, et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S43 - S54. [Abstract] [Full Text] [PDF]

				C. G. Elliott, L. Brown, M. Hegewald, and P. Zimmerman A Pathogenetic Paradigm for Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., May 15, 2009; 179(10): 967 - 967. [Full Text] [PDF]

				V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619. [Full Text] [PDF]

				Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation, April 28, 2009; 119(16): 2250 - 2294. [Full Text] [PDF]

				L. J. Rubin BMPR2 Mutation and Outcome in Pulmonary Arterial Hypertension: Clinical Relevance to Physicians and Patients Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1300 - 1301. [Full Text] [PDF]

				B. Sztrymf, F. Coulet, B. Girerd, A. Yaici, X. Jais, O. Sitbon, D. Montani, R. Souza, G. Simonneau, F. Soubrier, et al. Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers of BMPR2 Mutation Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1377 - 1383. [Abstract] [Full Text] [PDF]

				G. Lagna, M. M. Ku, P. H. Nguyen, N. A. Neuman, B. N. Davis, and A. Hata Control of Phenotypic Plasticity of Smooth Muscle Cells by Bone Morphogenetic Protein Signaling through the Myocardin-related Transcription Factors J. Biol. Chem., December 21, 2007; 282(51): 37244 - 37255. [Abstract] [Full Text] [PDF]

				S. Jain, H. Ventura, and B. deBoisblanc Pathophysiology of Pulmonary Arterial Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 104 - 109. [Abstract] [PDF]